'Sensing' the link between type 1 and type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 8, 2011, Pages 913-918

  Tsui, Hubert ^a   Paltser, Geoffrey ^a   Chan, Yin ^a   Dorfman, Ruslan ^a   Dosch, H Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Inflammation; Obesity; Sensory innervation; TRPV1; Type 1 diabetes; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

DIABETOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL HYPERPLASIA; PRIORITY JOURNAL; REVIEW; SENSORY NERVE; SENSORY NERVE CELL;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; INSULIN RESISTANCE; MICE; MICE, INBRED NOD; OBESITY; SENSORY RECEPTOR CELLS; TRPV CATION CHANNELS;

EID: 80855131172     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1279     Document Type: Review

References (46)

1. Tsui H, Razavi R, Chan Y, Yantha J, Dosch HM. 'Sensing' autoimmunity in type 1 diabetes. Trends Mol Med 2007; 13: 405-413.
2. + sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell 2006; 127: 1123-1135.
3. Tsui H, Winer S, Chan Y, et al. Islet glia, neurons, and beta cells. Ann N Y Acad Sci 2008; 1150: 32-42.
4. Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009; 15: 921-929.
5. Dorfman R, Tsui H, Salter MW, Dosch HM. TRPV1 genetics. In Vanniloid Receptor TRPV1 in Drug Discovery, Arthur G, Faltinek CR (eds). J Wiley & Sons: Hoboken, NJ, 2010; 471: 134-150.
6. Tsui H, Dorfman R, Salter MW, Dosch HM. The role of TRPV1 in diabetes. In Vanniloid Receptor TRPV1 in Drug Discovery, Gomtsyan A, Faltynek CR (eds). J Wiley & Sons: Hoboken, NJ, 2010; 471: 423-448.
7. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 2004; 271: 1814-1819.
8. Nagy I, Santha P, Jancso G, Urban L. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004; 500: 351-369.
9. Christianson JA, Bielefeldt K, Altier C, et al. Development, plasticity and modulation of visceral afferents. Brain Res Rev 2009; 60: 171-186.
10. Van Buren JJ, Bhat S, Rotello R, Pauza ME, Premkumar LS. Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol Pain 2005; 1: 17.
11. Rosmalen JG, Homo-Delarche F, Durant S, Kap M, Leenen PJ, Drexhage HA. Islet abnormalities associated with an early influx of dendritic cells and macrophages in NOD and NODscid mice. Lab Invest 2000; 80: 769-777.
12. Nakayama M, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435: 220-223.
13. Ortega-Rodriguez E, Levy-Marchal C, Tubiana N, Czernichow P, Polak M. Emergence of type 2 diabetes in an hospital based cohort of children with diabetes mellitus. Diabetes Metab 2001; 27: 574-578.
14. Pereira MA, Jacobs DR, Jr, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA study. JAMA 2002; 287: 2081-2089.
15. Brooks-Worrell B, Palmer JP. Is diabetes mellitus a continuous spectrum? Clin Chem 2011; 57: 158-161.
16. Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JP. Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 2011; 34: 168-173.
17. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
18. Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien YH. Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc Natl Acad Sci U S A 2006; 103: 12475-12480.
19. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-2125.
20. Motter AL, Ahern GP. TRPV1-null mice are protected from diet-induced obesity. FEBS Lett 2008; 582: 2257-2262.
21. Wang Y, Apicella A, Jr, Lee SK, et al. A glial DEG/ENaC channel functions with neuronal channel DEG-1 to mediate specific sensory functions in C. elegans. EMBO J 2008; 27: 2388-2399.
22. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
23. Grankvist K, Marklund SL, Taljedal IB. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem J 1981; 199: 393-398.
24. Tsui H, Chan Y, Tang L, et al. Targeting of pancreatic glia in type 1 diabetes. Diabetes 2008; 57: 918-928.
25. Guillot E, Coste A, Angel I. Involvement of capsaicin-sensitive nerves in the regulation of glucose tolerance in diabetic rats. Life Sci 1996; 59: 969-977.
26. Iwasaki Y, Tamura Y, Inayoshi K, et al. TRPV1 agonist monoacylglycerol increases UCP1 content in brown adipose tissue and suppresses accumulation of visceral fat in mice fed a high-fat and high-sucrose diet. Biosci Biotechnol Biochem 2011; 75: 904-909.
27. Kang JH, Goto T, Han IS, Kawada T, Kim YM, Yu R. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity (Silver Spring) 2010; 18: 780-787.
28. Tanaka H, Shimaya A, Kiso T, Kuramochi T, Shimokawa T, Shibasaki M. Enhancednsulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci 2011; 88: 559-563.
29. Zhu Z, Luo Z, Ma S, Liu D. TRP channels and their implications in metabolic diseases. Pflugers Arch 2011; 461: 211-223.
30. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
31. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008; 57: 3239-3246.
32. Giordano A, Morroni M, Santone G, Marchesi GF, Cinti S. Tyrosine hydroxylase, neuropeptide Y, substance P, calcitonin gene-related peptide and vasoactive intestinal peptide in nerves of rat periovarian adipose tissue: an immunohistochemical and ultrastructural investigation. J Neurocytol 1996; 25: 125-136.
33. Gonzalez-Muniesa P, Bing C, Trayhurn P. Upregulation of the expression of inflammatory and angiogenic markers in human adipocytes by a synthetic cannabinoid, JTE-907. Horm Metab Res 2010; 42: 710-717.
34. Zhang LL, Yan Liu D, Ma LQ, et al. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res 2007; 100: 1063-1070.
35. Shi H, Song CK, Giordano A, Cinti S, Bartness TJ. Sensory or sympathetic white adipose tissue denervation differentially affects depot growth and cellularity. Am J Physiol Regul Integr Comp Physiol 2005; 288: R1028-R1037.
36. Nishimura S, Manabe I, Nagasaki M, et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest 2008; 118: 710-721.
37. Bartness TJ, Shrestha YB, Vaughan CH, Schwartz GJ, Song CK. Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol Cell Endocrinol 2010; 318: 34-43.
38. Karagiannides I, Stavrakis D, Bakirtzi K, et al. Substance P (SP)-neurokinin-1 receptor (NK-1R) alters adipose tissue responses to high-fat diet and insulin action. Endocrinology 2011; 152: 2197-2205.
39. Caspar-Bauguil S, Cousin B, Galinier A, et al. Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett 2005; 579: 3487-3492.
40. Wu H, Ghosh S, Perrard XD, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007; 115: 1029-1038.
41. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002.
42. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009; 15: 914-920.
43. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15: 930-939.
44. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009; 15: 940-945.
45. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008; 123: 398-410.
46. Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 2011; 17: 610-617.